Please check your internet connection and try again.
# Mega-CV Duo (Amoxicillin/Clavulanate Potassium)
## Overview
Mega-CV Duo is a fixed-dose combination antibiotic consisting of amoxicillin (a beta-lactam) and clavulanate potassium (a beta-lactamase inhibitor). The clavulanate component expands the spectrum of activity to include beta-lactamase-producing bacteria that are otherwise resistant to amoxicillin alone.
## Primary Indications
* Community-acquired pneumonia
* Acute bacterial sinusitis
* Acute otitis media
* Skin and skin structure infections
* Urinary tract infections
* Lower respiratory tract infections
## Adult Dosing
Standard dosing is based on the amoxicillin component.
* **Mild to Moderate Infections:** 500 mg amoxicillin/125 mg clavulanate every 8 hours or 875 mg/125 mg every 12 hours.
* **Severe Infections:** 875 mg/125 mg every 8 to 12 hours.
* **Maximum Dose:** The clavulanate component limits the maximum dose to avoid hepatotoxicity and GI distress. Do not exceed 875 mg amoxicillin/125 mg clavulanate per dose.
## Pediatric Dosing
Dosing is strictly weight-based (calculated as mg of amoxicillin component).
* **General Recommendation:** 20 to 45 mg/kg/day in divided doses every 8–12 hours, depending on the severity of the infection.
* **Recurrent/Resistant Otitis Media:** 80–90 mg/kg/day divided every 12 hours.
* *Note:* Always verify the ratio of the formulation provided (e.g., 200/28, 400/57, or 600/42.9 mg/5 mL) to ensure the correct clavulanate dose is administered, as some concentrations are not interchangeable.
## Dose Adjustments
* **Renal Impairment:** Reduce frequency for CrCl < 30 mL/min. Avoid the 875 mg strength in patients with severe renal impairment (CrCl < 30 mL/min) because the clavulanate load cannot be adjusted independently.
* **Hepatic Impairment:** Use with caution; monitor hepatic function regularly.
## Contraindications
* Known hypersensitivity to amoxicillin, clavulanate, or other penicillins/beta-lactams.
* History of cholestatic jaundice or hepatic dysfunction associated with previous amoxicillin/clavulanate therapy.
## Adverse Effects
* **Common:** Diarrhea (often dose-related due to clavulanate), nausea, vomiting, abdominal pain, skin rash/urticaria.
* **Serious:** Clostridioides difficile-associated diarrhea (CDAD), hepatotoxicity (cholestatic jaundice), anaphylaxis, Stevens-Johnson syndrome.
## Key Drug Interactions
* **Probenecid:** Decreases renal tubular secretion of amoxicillin, increasing serum levels.
* **Oral Contraceptives:** Potential for decreased efficacy (evidence base is debated, but barrier protection is often advised).
* **Warfarin:** May increase INR and risk of bleeding; monitor PT/INR closely when initiating or stopping therapy.
* **Methotrexate:** May decrease renal clearance of methotrexate, increasing risk of toxicity.
## Monitoring
* Monitor for signs of anaphylaxis during the first dose.
* Evaluate LFTs if therapy duration exceeds 14 days.
* Monitor for signs of CDAD (persistent watery or bloody diarrhea).
* Monitor renal function in patients with pre-existing impairment.
## Clinical Pearls
* **GI Tolerance:** Administer at the start of a meal to minimize GI upset and improve absorption.
* **Diarrhea Management:** If diarrhea is dose-limiting, consider switching products or assessing if the clavulanate ratio is inappropriate for the patient's age.
* **Formulation Caution:** Not all strengths are bioequivalent. Always calculate based on the specific mg of amoxicillin provided in the local formulary to prevent toxicity or under-dosing.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and interaction profiles may change. Always verify current prescribing information in official resources (e.g., FDA labels, BNF, or local institutional formularies) before prescribing or administering medication.
